CN110897995A - 一种美白膏霜及其制备方法 - Google Patents
一种美白膏霜及其制备方法 Download PDFInfo
- Publication number
- CN110897995A CN110897995A CN201911283243.XA CN201911283243A CN110897995A CN 110897995 A CN110897995 A CN 110897995A CN 201911283243 A CN201911283243 A CN 201911283243A CN 110897995 A CN110897995 A CN 110897995A
- Authority
- CN
- China
- Prior art keywords
- phase
- parts
- whitening
- stirring
- whitening cream
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002087 whitening effect Effects 0.000 title claims abstract description 64
- 239000006071 cream Substances 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title abstract description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 48
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims abstract description 32
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims abstract description 28
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims abstract description 28
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims abstract description 18
- 108010087806 Carnosine Proteins 0.000 claims abstract description 18
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 18
- 229940044199 carnosine Drugs 0.000 claims abstract description 18
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims abstract description 18
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 18
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 18
- 239000006166 lysate Substances 0.000 claims abstract description 15
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims abstract description 14
- 229960000458 allantoin Drugs 0.000 claims abstract description 14
- 238000000855 fermentation Methods 0.000 claims abstract description 14
- 230000004151 fermentation Effects 0.000 claims abstract description 14
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 claims abstract description 13
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims abstract description 13
- 229960000401 tranexamic acid Drugs 0.000 claims abstract description 12
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims abstract description 12
- -1 polydimethylsiloxane Polymers 0.000 claims abstract description 11
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims abstract description 10
- 241001135917 Vitellaria paradoxa Species 0.000 claims abstract description 10
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims abstract description 10
- 229940042585 tocopherol acetate Drugs 0.000 claims abstract description 10
- 229920006007 hydrogenated polyisobutylene Polymers 0.000 claims abstract description 9
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229940057910 shea butter Drugs 0.000 claims abstract description 9
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims abstract description 9
- 241000235346 Schizosaccharomyces Species 0.000 claims abstract description 8
- 238000003756 stirring Methods 0.000 claims description 52
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 36
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 27
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 25
- 238000001816 cooling Methods 0.000 claims description 25
- 239000003995 emulsifying agent Substances 0.000 claims description 22
- 238000010438 heat treatment Methods 0.000 claims description 20
- 239000008213 purified water Substances 0.000 claims description 20
- 239000002562 thickening agent Substances 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 18
- 239000003921 oil Substances 0.000 claims description 18
- 230000008719 thickening Effects 0.000 claims description 16
- 239000003381 stabilizer Substances 0.000 claims description 15
- 150000005846 sugar alcohols Polymers 0.000 claims description 15
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 14
- 230000003078 antioxidant effect Effects 0.000 claims description 14
- 239000003963 antioxidant agent Substances 0.000 claims description 13
- 239000007957 coemulsifier Substances 0.000 claims description 13
- 230000002335 preservative effect Effects 0.000 claims description 12
- 239000003755 preservative agent Substances 0.000 claims description 11
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 10
- 235000011187 glycerol Nutrition 0.000 claims description 9
- 238000005070 sampling Methods 0.000 claims description 9
- 229940087068 glyceryl caprylate Drugs 0.000 claims description 8
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 claims description 8
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 229920001577 copolymer Polymers 0.000 claims description 7
- 229930182478 glucoside Natural products 0.000 claims description 7
- 229940100460 peg-100 stearate Drugs 0.000 claims description 7
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- PQUXFUBNSYCQAL-UHFFFAOYSA-N 1-(2,3-difluorophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(F)=C1F PQUXFUBNSYCQAL-UHFFFAOYSA-N 0.000 claims description 5
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 claims description 5
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 5
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 5
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 claims description 5
- 229920002125 Sokalan® Polymers 0.000 claims description 5
- 235000013871 bee wax Nutrition 0.000 claims description 5
- 239000012166 beeswax Substances 0.000 claims description 5
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 5
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims description 5
- 229960001631 carbomer Drugs 0.000 claims description 5
- 229940082500 cetostearyl alcohol Drugs 0.000 claims description 5
- 230000001804 emulsifying effect Effects 0.000 claims description 5
- 238000011049 filling Methods 0.000 claims description 5
- 238000007689 inspection Methods 0.000 claims description 5
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 claims description 5
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 5
- 229960001679 octinoxate Drugs 0.000 claims description 5
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 5
- 229940068968 polysorbate 80 Drugs 0.000 claims description 5
- 229920000053 polysorbate 80 Polymers 0.000 claims description 5
- 229940047670 sodium acrylate Drugs 0.000 claims description 5
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 5
- 229940001584 sodium metabisulfite Drugs 0.000 claims description 5
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 5
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 5
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical group [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 claims description 2
- 229940035437 1,3-propanediol Drugs 0.000 claims description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 2
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 2
- 229940048053 acrylate Drugs 0.000 claims description 2
- 229920006037 cross link polymer Polymers 0.000 claims description 2
- 229940075529 glyceryl stearate Drugs 0.000 claims description 2
- RGUVUPQQFXCJFC-UHFFFAOYSA-N n-hydroxyoctanamide Chemical compound CCCCCCCC(=O)NO RGUVUPQQFXCJFC-UHFFFAOYSA-N 0.000 claims description 2
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims description 2
- 235000010265 sodium sulphite Nutrition 0.000 claims description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims 1
- 230000003797 telogen phase Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 30
- 229960004106 citric acid Drugs 0.000 abstract description 14
- 208000003351 Melanosis Diseases 0.000 abstract description 7
- 230000008439 repair process Effects 0.000 abstract description 7
- 230000002195 synergetic effect Effects 0.000 abstract description 6
- 239000004205 dimethyl polysiloxane Substances 0.000 abstract description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 abstract description 4
- 206010014970 Ephelides Diseases 0.000 abstract description 3
- 235000013399 edible fruits Nutrition 0.000 abstract description 3
- 238000013329 compounding Methods 0.000 abstract 1
- 231100000957 no side effect Toxicity 0.000 abstract 1
- 229920005989 resin Polymers 0.000 abstract 1
- 239000011347 resin Substances 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 55
- 239000000047 product Substances 0.000 description 30
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 28
- 230000000052 comparative effect Effects 0.000 description 16
- 235000019198 oils Nutrition 0.000 description 15
- 238000004321 preservation Methods 0.000 description 12
- 235000006708 antioxidants Nutrition 0.000 description 11
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 8
- 230000003020 moisturizing effect Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 6
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 230000003712 anti-aging effect Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000000049 pigment Substances 0.000 description 5
- 238000007599 discharging Methods 0.000 description 4
- 239000003974 emollient agent Substances 0.000 description 4
- 210000001339 epidermal cell Anatomy 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 229960003966 nicotinamide Drugs 0.000 description 4
- 235000005152 nicotinamide Nutrition 0.000 description 4
- 239000011570 nicotinamide Substances 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 238000013112 stability test Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000000151 deposition Methods 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920000832 Cutin Polymers 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003560 epithelium corneal Anatomy 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000009965 odorless effect Effects 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010027146 Melanoderma Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/442—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof substituted by amido group(s)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8105—Compositions of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Compositions of derivatives of such polymers
- A61K8/8111—Homopolymers or copolymers of aliphatic olefines, e.g. polyethylene, polyisobutene; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
- A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cosmetics (AREA)
Abstract
本发明公开了一种美白膏霜及其制备方法,美白膏霜主要由1‑甲基乙内酰脲‑2‑酰亚胺、二裂酵母发酵产物溶胞物和肌肽三种美白成分复配,达成协同美白的作用,能起到美白祛斑的作用,再辅以透明质酸钠、尿囊素、对羟基苯乙酮、EDTA二钠、烟酰胺、氢化聚异丁烯、辛酸葵酸甘油三酯、牛油果树果脂、聚二甲硅氧烷、柠檬酸、凝血酸和生育酚乙酸酯制备而成,既能起到保湿修护肌肤,又安全无副作用,效果全面。
Description
技术领域
本发明涉及日化技术领域,具体涉及一种美白膏霜及其制备方法。
背景技术
黑色素是影响皮肤白皙透亮的最主要因素。由于年龄的增长和外部环境污染、生活压力等因素的影响,人体新陈代谢的平衡遭到破坏,皮肤所需的营养供应趋于缓慢,色素母细胞就会变得很活跃,新陈代谢不顺畅、或内分泌失调身体处于感状态下,使色素问题加剧,肌肤裸露在强烈的紫外线下、精神上受到压力等原因,都会加剧的色素的沉积,导致黑色素色斑产生,使得肤色暗哑粗糙。现在市面上流行的大部分美白祛斑霜使用感观差,用后没效果,功能单一,有些产品使用后还会有一些副作用,有些更为了获取利益,快速美白,在产品还添加一些重金属等违禁成分,可能会导致色素沉积,使色斑越长越多,更为严重的甚至诱发其他疾病,肤色反弹等。
目前市面上的美白祛斑产品大多添加一些中药提取物、矿物质(珍珠粉)、维生素C及其衍生物、羟基乙酸等,由于黑色素形成的原因是多方面的,如果仅添加单一成分的美白成分,美白效果不明显。
发明内容
为了克服现有技术的不足,本发明的目的在于提供一种美白膏霜及其制备方法,该美白膏霜经过多种美白产品协同复配,既能保湿修护皮肤,又能起到美白祛斑的作用,并且安全无副作用。
本发明的目的采用如下技术方案实现:
一种美白膏霜,由A相、B相、C相、D相和E相制成;
A相包括:多元醇3-10份、透明质酸钠0.01-0.5份、增稠剂0.1-0.5份、烟酰胺0.5-5份、尿囊素0.1-0.5份、EDTA二钠0.01-0.2份、对羟基苯乙酮0.1-0.5份和纯化水若干份;B相包括:乳化剂1-5份、氢化聚异丁烯2-5份、辛酸葵酸甘油三酯3-8份、牛油果树果脂1-3份、蜂蜡0.5-3份、生育酚乙酸酯0.1-1份、甲氧基肉桂酸乙基己酯0.5-3份、丁羟甲苯0.01-0.1份、鲸蜡硬脂醇0.5-3份;C相包括:增稠稳定剂0.2-1份;D相包括:柠檬酸0.1-1份、肌肽0.1-2份、凝血酸0.5-5份、二裂酵母发酵产物溶胞物0.1-5份、1-甲基乙内酰脲-2-酰亚胺0.1-3份、抗氧化剂0.01-0.2份、防腐剂0.6-1.5份和香精0.01-0.2份。
美白成分说明:
1-甲基乙内酰脲-2-酰亚胺是一种天然的氨基酸衍生物,属胍类化合物,普遍存在于哺乳动物细胞中,具有重要的生物学功能,对皮肤的亲和性好,能调节人体细胞的生长和转化,有抑制酪氨酸酶及黑色素蛋白质的生物合成的作用,同时能改善皮肤细胞的新陈代谢,增强深层毛细血管的通透量,加速表皮色素细胞和表皮细胞群的更新代谢,从而降底色素沉着的程度和表皮过度角质化,增加皮肤的透明度,让皮肤显得白皙,水润。
二裂酵母发酵产物溶胞物,通过生物技术合成的双歧杆菌溶胞产物组成。包含代谢产物,细胞质,细胞壁和多糖复合物。这种借助生物技术获得的活性物质能特异性地支持皮肤自身的保护和修复基质,可有效保护皮肤,不受紫外线引起的损伤,能帮助预防表皮及真皮的光老化和能促进细胞的修复。二裂酵母发酵产物溶孢物,立马含有维他命B群、矿物质、氨基酸等有益护肤的小分子,这些小分子都是优质护肤高营养成份,他们可以加强角质层的代谢,捕获体内自由基,抑制脂质的过氧化,具有美白、抗衰老的功能。
肌肽,是一种天然存在的二肽,存在于脊椎动物的骨骼肌和大脑等组织中,由β一丙氨酸和L组氨酸组成。可以清除自由基,抗氧化,还有优越的抗糖基化作用,同时还具有恢复疲劳、延缓衰老、预防疾病等生理功能。肌肽通过清除体内自由基、抗氧化、抗糖基化来预防紫外线对人体皮肤的伤害,减少的黑色素形成以及沉积,并有效防止机体新陈代谢过程中细胞膜和细胞不饱和脂肪酸等易氧化物质被氧化,从而达到美白祛黄的作用。
其他成分说明:
透明质酸钠:又名玻璃酸钠、玻尿酸钠、糖醛酸钠,透明质酸钠又称玻尿酸钠,属于肌肤调理剂,是一种酸性粘多糖,天然存在于角膜皮中,可吸收其本身重量1000倍水分,以达到通过保留皮肤水分、阻止水分经表皮流失,以及当皮肤受到损伤时的屏障修复,令皮肤使用后不会感到干燥,增加光泽,它可以改善皮肤营养代谢,使皮肤柔、光滑、去皱、增加弹性、防止衰老,在保湿的同时又是良好的透皮吸收促进剂。与其他营养成分配合使用,可以起到促进营养吸收的更理想效果。
尿囊素:能够帮助皮肤抗炎、舒缓并促进细胞修复,同时可降低角质层细胞的粘着力,加速表皮细胞更新。
对羟基苯乙酮:是一种天然植物提取物,具有抗氧化和舒缓作用的,同时可作为传统防腐剂的替代品,具有增效防腐的作用,能够促进各种防腐剂功效。
EDTA二钠:主要作螯合剂使用,也可协同防腐作用。并且对防腐体系和抗氧化体系有一定协同增效作用。
烟酰胺:又名维生素B3,是一种水溶性维生素且是维生素B族中的一员,分子较小,具有良好透皮吸收性,它在抑制黑色素沉着、抗炎等方面也有很好的功效,它能抑制黑色素颗粒的形成,及其黑色素颗粒在向表皮细胞上行至角质层,有效抑制黑色素向角质细胞传递,更重要的是当有部分黑色素不可避免地达到表层皮肤后,烟酰胺又能通过加速皮肤细胞的更新速度从而促进含有黑色素的细胞脱落。从内到外,实现改善肤质,达到净白肌肤的效果,同时烟酰胺能够维持肌肤含水量,促进真皮层微循环。烟酰胺还能极大减少或消除皮肤老化现象,比如皱纹、起皮、毛孔粗大等,减少自由基对皮肤的伤害,起到预防老化、修复皮肤和减少面部暗沉的作用。
氢化聚异丁烯:润肤剂,具有角鲨烷的化妆品特性,因而被称为合成角鲨烷,抗氧化性和热稳定性优异,肤感滋润而不油腻,对皮肤有较好的亲和性,不会引起过敏和刺激,并能加速配方中其他活性成分向皮肤中渗透;具有较低的极性和中等的铺展性,且纯净、无色、无异味;还可抑制霉菌的生长。
辛酸癸酸甘油三酯:润肤剂,是高清爽度无味油脂,属棕榈油或椰子油的衍生物,它是使用热分馏方法提取。由于它和人体皮肤有兼容的特征,它有着不油腻质感,加入乳霜或乳液中可改进其延伸性,有润滑和使肌肤柔软的效果。并有过滤紫外光的功能,为椰子中的提取物,化妆品中作柔润剂、溶剂、促渗透剂来使用。
牛油果树果脂:从牛油果树的果实中提取而成,含有丰富的不饱和脂肪酸,能够加强皮肤的保湿能力,对干性皮肤即角质受损的肌肤能加以滋润。同时可以调节产品的流动性,改善粘度,提高产品的感官品质和使用肤感。
聚二甲基硅氧烷:润肤剂,有优异丝滑感和耐久性,并能在皮肤形成一层均匀的具有防水性的保护膜,保湿度好,光泽性好。抗紫外线辐射的性能好,它在紫外线下不会氧化变质而引起对皮肤刺激作用,抗静电性能,透气性好,对化妆品其他组成,特别是活性成分没有任何不良影响匹配性好。无毒、无臭、无味,对皮肤不会引起刺激和过敏,安全性高。
柠檬酸:柠檬酸从柠檬中提取,属于果酸中的一种。化妆品中主要作为螯合剂、缓冲剂、酸碱调节剂,还可作为天然防腐剂使用,是人体中重要的柠檬酸循环不可少的物质。它能加快角质更新,有助于皮肤中黑色素剥落,收敛毛孔。并对皮肤可以起到保湿、美白的作用,有助于改善皮肤黑斑、粗糙等情况。
凝血酸又名传明酸、氨甲环酸,它是一种蛋白酶抑制剂,能抑制蛋白酶对肽键水解的催化作用,从而能阻止发炎性蛋白酶的活性,进而抑制黑斑部位的表皮细胞机能紊乱,阻止黑色素的聚集,是黑斑不再增加,同时它能有效的还原已生成的黑色素,能有效阻止因紫外线生产黑色素的途径,让黑斑不再变浓扩大,有效防止皮肤色素沉积,凝血酸影响皮肤颜色或形成色斑这阶段前起很大的作用。
生育酚乙酸酯:生育酚乙酸酯属于维生素E的衍生物,在化妆品中常做抗氧化剂使用,有很好的抗氧化效果,它是一种油溶性的天然物质,对肌肤是很好的营养滋润剂,添加于保养品中,能够避免油脂的酸败氧化,安定油脂。在保湿和维持结缔组织,以及保护皮肤不受紫外线伤害都有很好表现,该成分能使肌肤触感柔软并保持肌肤水分,促进伤口愈合、预防发炎防止肌肤粗糙皲裂、改善黑斑,安全风险指数不高故使用广泛。
本发明的美白膏霜主要由1-甲基乙内酰脲-2-酰亚胺、二裂酵母发酵产物溶胞物和肌肽三种美白成分复配,达成协同美白的作用,能起到美白祛斑的作用,再辅以透明质酸钠、尿囊素、对羟基苯乙酮、EDTA二钠、烟酰胺、氢化聚异丁烯、辛酸葵酸甘油三酯、牛油果树果脂、聚二甲硅氧烷、柠檬酸、凝血酸和生育酚乙酸酯制备而成,既能起到保湿修护肌肤,又安全无副作用,效果全面。
进一步,所述多元醇包括甘油、丁二醇、丙二醇中的一种或几种。其中甘油、丙二醇、丁二醇作为保湿剂,主要是给皮肤补充水分,可以通过控制皮肤与周围空气之间水分的交换使皮肤维持在高于正常水含量的平衡状态,起到减轻皮肤干燥的作用,同时还能保护皮肤受外界刺激,并且可以促进受损皮肤的修复。
再进一步,所述增稠剂包括卡波姆、丙烯酸(酯)类/C10-30烷醇丙烯酸酯交联聚合物和丙烯酸羟乙酯/丙烯酰二甲基牛磺酸钠共聚物中的一种或几种。
进一步,所述乳化剂包括主乳化剂和助乳化剂,主乳化剂和助乳化剂的重量比为1-3:1;其中,主化剂为C14-22醇和C12-20烷基葡糖苷的混合物;助乳化剂为甘油硬脂酸酯和PEG-100硬脂酸酯的混合物。
再进一步,所述C14-22醇和C12-20烷基葡糖苷的重量比为1:1;甘油硬脂酸酯和PEG-100硬脂酸酯的重量比为1:1。
进一步,所述增稠稳定剂为重量比为4-7:2-4:1的丙烯酸钠/丙烯酰二甲基牛磺酸钠共聚物、异十六烷和聚山梨醇酯-80的混合物。其中,最优比为5:3:1。
再进一步,所述抗氧化剂为亚硫酸钠和/或焦亚硫酸钠。
进一步,所述防腐剂为重量比1:7-10:1的辛酰羟肟酸、1,3-丙二醇和甘油辛酸酯的混合物。其中,最优比为1:8:1。
美白膏霜的制备方法,包括以下步骤:
1)将A相中的对羟基苯乙酮加入多元醇中,加热到80-85℃中搅拌溶解;
2)将A相中的增稠剂和95%的纯化水加入到水锅中,搅拌至增稠剂完全溶解,再加入烟酰胺、尿囊素、EDTA二钠和透明质酸钠,加热到80-85℃,搅拌溶解后加入步骤1)所得的溶液,继续搅拌保温,得到水相A;其中,搅拌速度为50-80rpm,保温时间为20-30min。
3)将B相包括的全部原料加入到油锅中,加热搅拌,得到油相B;其中,搅拌速度为50-80rpm,保温时间为20-30min。
4)将水相A加入乳化锅中,均质2-3min后,再加入油相B,均质5-8min,然后搅拌保温;
5)将步骤4)所得溶液降温至70℃,加入C相中的增稠稳定剂,均质2-3min,搅拌保温20min;其中,搅拌速度为40-60rpm,保温时间为30-60min。
6)将A相剩余的5%的纯化水加热到80-85℃,冷却到室温备用;
7)将D相中的柠檬酸加入到2/5的步骤6)所得的溶液中,充分溶解备用;
8)将D相中的肌肽加入到剩余3/5的步骤6)所得的溶液中,充分溶解备用;
9)将步骤8)所得溶液冷却降温至40℃,加入步骤3)、步骤4)所得溶液和D相剩余的全部原料,搅拌溶解,冷却后即得美白膏霜。
10)冷却到35℃,取样检验;
11)待检验合格后,出料,静置,进行灌装和包装;
12)进行成品抽检,检验合格后,入库。
相比现有技术,本发明的有益效果在于:
(1)本发明的美白膏霜主要由1-甲基乙内酰脲-2-酰亚胺、二裂酵母发酵产物溶胞物和肌肽三种美白成分复配,达成协同美白的作用,能起到美白祛斑的作用,再辅以透明质酸钠、尿囊素、对羟基苯乙酮、EDTA二钠、烟酰胺、氢化聚异丁烯、辛酸葵酸甘油三酯、牛油果树果脂、聚二甲硅氧烷、柠檬酸、凝血酸和生育酚乙酸酯制备而成,既能起到保湿修护肌肤,又安全无副作用,效果全面;
(2)本发明的美白膏霜的形状和外观即使在46℃和-10℃的储存环境下以及在常温保存36个月后仍能保持白色膏状,稳定性良好。
具体实施方式
下面,结合具体实施方式,对本发明做进一步描述,需要说明的是,在不相冲突的前提下,以下描述的各实施例之间或各技术特征之间可以任意组合形成新的实施例。
实施例1
一种美白膏霜,由A相、B相、C相、D相和E相制成;
A相包括:多元醇3份、透明质酸钠0.02份、增稠剂0.1份、烟酰胺1份、尿囊素0.1份、EDTA二钠0.01份、对羟基苯乙酮0.2份和纯化水若干份;B相包括:乳化剂2份、氢化聚异丁烯2份、辛酸葵酸甘油三酯8份、牛油果树果脂1份、蜂蜡3份、生育酚乙酸酯0.2份、甲氧基肉桂酸乙基己酯0.5份、丁羟甲苯0.02份、鲸蜡硬脂醇3份;C相包括:增稠稳定剂0.8份;D相包括:柠檬酸0.2份、肌肽0.1份、凝血酸1份、二裂酵母发酵产物溶胞物0.2份、1-甲基乙内酰脲-2-酰亚胺0.5份、抗氧化剂0.01份、防腐剂1.2份和香精0.02份。
其中,所述的多元醇为甘油和丙二醇,其中甘油和丙二醇的重量比为1:1;所述乳化剂包括主乳化剂和助乳化剂,主乳化剂和助乳化剂的重量比为1:1;其中,主化剂为重量比为1:1的C14-22醇与C12-20烷基葡糖苷的混合物,助乳化剂为重量比为1:1的甘油硬脂酸酯与PEG-100硬脂酸酯的混合物;所述的增稠剂为卡波姆;所述的抗氧化剂为焦亚硫酸钠;所述防腐剂为辛酰羟肟酸、1,3-丙二醇、甘油辛酸酯的混合物,所述辛酰羟肟酸、1,3-丙二醇、甘油辛酸酯的重量比为1:7:1。所述增稠稳定剂为重量比为4:2:1的丙烯酸钠/丙烯酰二甲基牛磺酸钠共聚物、异十六烷和聚山梨醇酯-80的混合物。纯化水补足100份,纯化水为71.82份。
美白膏霜的制备方法,包括以下步骤:
1)将A相中的对羟基苯乙酮加入多元醇中,加热到80℃中搅拌溶解;
2)将A相中的增稠剂和95%的纯化水加入到水锅中,搅拌至增稠剂完全溶解,再加入烟酰胺、尿囊素、EDTA二钠和透明质酸钠,加热到80℃,搅拌溶解后加入步骤1)所得的溶液,继续搅拌保温,得到水相A;其中,搅拌速度为80rpm,保温时间为30min。
3)将B相包括的全部原料加入到油锅中,加热至80℃搅拌,得到油相B;其中,搅拌速度为80rpm,保温时间为30min。
4)将水相A加入乳化锅中,均质2min后,再加入油相B,均质5min,然后搅拌保温;
5)将步骤4)所得溶液降温至70℃,加入C相中的增稠稳定剂,均质2min,搅拌保温20min;其中,搅拌速度为60rpm,保温时间为60min。
6)将A相剩余的5%的纯化水加热到80℃,冷却到室温备用;
7)将D相中的柠檬酸加入到2/5的步骤6)所得的溶液中,充分溶解备用;
8)将D相中的肌肽加入到剩余3/5的步骤6)所得的溶液中,充分溶解备用;
9)将步骤5)所得溶液冷却降温至40℃,加入步骤7)、步骤8)所得溶液和D相剩余的全部原料,搅拌溶解,冷却后即得美白膏霜。
10)冷却到35℃,取样检验;
11)待检验合格后,出料,静置,进行灌装和包装;
12)进行成品抽检,检验合格后,入库。
实施例2
一种美白膏霜,由A相、B相、C相、D相和E相制成;
A相包括:多元醇8份、透明质酸钠0.1份、增稠剂0.25份、烟酰胺4份、尿囊素0.2份、EDTA二钠0.1份、对羟基苯乙酮0.3份和纯化水若干份;B相包括:乳化剂3份、氢化聚异丁烯4份、辛酸葵酸甘油三酯5份、牛油果树果脂3份、蜂蜡1.5份、生育酚乙酸酯0.5份、甲氧基肉桂酸乙基己酯2份、丁羟甲苯0.05份、鲸蜡硬脂醇2份;C相包括:增稠稳定剂0.5份;D相包括:柠檬酸0.8份、肌肽1份、凝血酸2份、二裂酵母发酵产物溶胞物3份、1-甲基乙内酰脲-2-酰亚胺1.5份、抗氧化剂0.05份、防腐剂1份和香精0.05份。
其中,所述的多元醇为甘油和丙二醇,其中甘油和丙二醇的重量比为1:1;所述乳化剂包括主乳化剂和助乳化剂,主乳化剂和助乳化剂的重量比为1:1;其中,主化剂为重量比为1:1的C14-22醇与C12-20烷基葡糖苷的混合物,助乳化剂为重量比为1:1的甘油硬脂酸酯与PEG-100硬脂酸酯的混合物;所述的增稠剂为卡波姆;所述的抗氧化剂为焦亚硫酸钠;所述防腐剂为辛酰羟肟酸、1,3-丙二醇、甘油辛酸酯的混合物,所述辛酰羟肟酸、1,3-丙二醇、甘油辛酸酯的重量比为1:8:1。所述增稠稳定剂为重量比为5:3:1的丙烯酸钠/丙烯酰二甲基牛磺酸钠共聚物、异十六烷和聚山梨醇酯-80的混合物。纯化水补足100份,纯化水为57.15份。
美白膏霜的制备方法,包括以下步骤:
1)将A相中的对羟基苯乙酮加入多元醇中,加热到82℃中搅拌溶解;
2)将A相中的增稠剂和95%的纯化水加入到水锅中,搅拌至增稠剂完全溶解,再加入烟酰胺、尿囊素、EDTA二钠和透明质酸钠,加热到82℃,搅拌溶解后加入步骤1)所得的溶液,继续搅拌保温,得到水相A;其中,搅拌速度为60rpm,保温时间为25min。
3)将B相包括的全部原料加入到油锅中,加热至82℃搅拌,得到油相B;其中,搅拌速度为60rpm,保温时间为25min。
4)将水相A加入乳化锅中,均质3min后,再加入油相B,均质6min,然后搅拌保温;
5)将步骤4)所得溶液降温至70℃,加入C相中的增稠稳定剂,均质3min,搅拌保温20min;其中,搅拌速度为50rpm,保温时间为50min。
6)将A相剩余的5%的纯化水加热到82℃,冷却到室温备用;
7)将D相中的柠檬酸加入到2/5的步骤2)所得的溶液中,充分溶解备用;
8)将D相中的肌肽加入到剩余的3/5步骤2)所得的溶液中,充分溶解备用;
9)将步骤5)所得溶液冷却降温至40℃,加入步骤7)、步骤8)所得溶液和D相剩余的全部原料,搅拌溶解,冷却后即得美白膏霜。
10)冷却到35℃,取样检验;
11)待检验合格后,出料,静置,进行灌装和包装;
12)进行成品抽检,检验合格后,入库。
实施例3
一种美白膏霜,由A相、B相、C相、D相和E相制成;
A相包括:多元醇8份、透明质酸钠0.1份、增稠剂0.25份、烟酰胺4份、尿囊素0.2份、EDTA二钠0.1份、对羟基苯乙酮0.3份和纯化水若干份;B相包括:乳化剂3份、氢化聚异丁烯4份、辛酸葵酸甘油三酯5份、牛油果树果脂3份、蜂蜡1.5份、生育酚乙酸酯0.5份、甲氧基肉桂酸乙基己酯2份、丁羟甲苯0.05份、鲸蜡硬脂醇2份;C相包括:增稠稳定剂0.5份;D相包括:柠檬酸0.8份、肌肽2份、凝血酸2份、二裂酵母发酵产物溶胞物5份、1-甲基乙内酰脲-2-酰亚胺3份、抗氧化剂0.08份、防腐剂1份和香精0.05份。
其中,所述的多元醇为甘油和丙二醇,其中甘油和丙二醇的重量比为1:1;所述乳化剂包括主乳化剂和助乳化剂,主乳化剂和助乳化剂的重量比为3:1;其中,主化剂为重量比为1:1的C14-22醇与C12-20烷基葡糖苷的混合物,助乳化剂为重量比为1:1的甘油硬脂酸酯与PEG-100硬脂酸酯的混合物;所述的增稠剂为卡波姆;所述的抗氧化剂为焦亚硫酸钠;所述防腐剂为辛酰羟肟酸、1,3-丙二醇、甘油辛酸酯的混合物,所述辛酰羟肟酸、1,3-丙二醇、甘油辛酸酯的重量比为1:10:1。所述增稠稳定剂为重量比为7:4:1的丙烯酸钠/丙烯酰二甲基牛磺酸钠共聚物、异十六烷和聚山梨醇酯-80的混合物。纯化水补足100份,纯化水为53.62份。
美白膏霜的制备方法,包括以下步骤:
1)将A相中的对羟基苯乙酮加入多元醇中,加热到85℃中搅拌溶解;
2)将A相中的增稠剂和95%的纯化水加入到水锅中,搅拌至增稠剂完全溶解,再加入烟酰胺、尿囊素、EDTA二钠和透明质酸钠,加热到85℃,搅拌溶解后加入步骤1)所得的溶液,继续搅拌保温,得到水相A;其中,搅拌速度为50rpm,保温时间为20min。
3)将B相包括的全部原料加入到油锅中,加热至85℃搅拌,得到油相B;其中,搅拌速度为50rpm,保温时间为20min。
4)将水相A加入乳化锅中,均质3min后,再加入油相B,均质8min,然后搅拌保温;
5)将步骤4)所得溶液降温至70℃,加入C相中的增稠稳定剂,均质2-3min,搅拌保温20min;其中,搅拌速度为40rpm,保温时间为30min。
6)将A相剩余的5%的纯化水加热到85℃,冷却到室温备用;
7)将D相中的柠檬酸加入到2/5的步骤2)所得的溶液中,充分溶解备用;
8)将D相中的肌肽加入到剩余的3/5步骤2)所得的溶液中,充分溶解备用;
9)将步骤5)所得溶液冷却降温至40℃,加入步骤7)、步骤8)所得溶液和D相剩余的全部原料,搅拌溶解,冷却后即得美白膏霜。
10)冷却到35℃,取样检验;
11)待检验合格后,出料,静置,进行灌装和包装;
12)进行成品抽检,检验合格后,入库。
对比例1
对比例1的配方在实施例2的基础上去掉了1-甲基乙内酰脲-2-酰亚胺,制备方法与实施例2相同。
对比例2
对比例2的配方在实施例2的基础上去掉了肌肽、1-甲基乙内酰脲-2-酰亚胺和二裂酵母发酵产物溶胞物,制备方法与实施例2相同。
功效测试
本实验采用实施例1-3提供的美白膏霜及对比例1-2进行志愿者测试评价实验,该实验包括60位女性志愿者,年龄在20-45周岁,分为5组进行测试,每组12人,测试时间为8周。5组测试者在8周内每晚涂抹实施例1-3和对比例1-2制备的美白膏霜。
采用表格测评的形式,由受试者自己评估使用时及其前后皮肤改善程度测试,下表示志愿者该产品的肤感、保湿度、过敏性、使用后对皮肤粗糙度、肤色等改善程度的测评结果。
各项使用效果总分为10分:9-10分为最高分,表示很好,7-8分表示较好,5-6分表示可接受,3-4分为比较差,1-2分为不能接受,分数越高表示志愿者越喜欢,效果越好。测评结果如表1所示,以下为各项平均得分。
表1实施例1-3和对比例1-2的项目指标数据表
项目 | 保湿效果 | 修护效果 | 抗衰效果 | 美白效果 | 祛斑效果 |
实施例1 | 8.2 | 7.5 | 6.5 | 7.5 | 6.2 |
实施例2 | 9.2 | 8.8 | 8.4 | 8.9 | 7.9 |
实施例3 | 9.5 | 8.5 | 8.0 | 8.6 | 7.5 |
对比例1 | 9.0 | 8.4 | 7.6 | 7.2 | 5.4 |
对比例2 | 8.0 | 6.5 | 6.3 | 5.9 | 4.6 |
从表1的数据可以看出,实施例1-3均能起到良好的保湿、修护、抗衰、美白和祛斑效果。在实施例1-3中,实施例2的保湿、修护、抗衰、美白和祛斑效果均优于实施例1和实施例3。实施例1-3中的肌肽、二裂酵母发酵产物溶胞物和1-甲基乙内酰脲-2-酰亚胺这三种成分的添加量是逐步增加的,但其功效效果并没有呈现替增的作用,所以配方中并不代表美白成份越多越好,各成份之间的配比要适量,共同协同才能达到更好的效果(本发明中的实施例1-3只是选择本发明配方的一小部分,并不代表实施例2就是最佳实验配比)。
对比例1与实施例2相比,缺少了1-甲基乙内酰脲-2-酰亚胺;对比例2与实施例相比,缺少了肌肽、二裂酵母发酵产物溶胞物和1-甲基乙内酰脲-2-酰亚胺。对比例1相比于实施例2而言,不添加1-甲基乙内酰脲-2-酰亚胺,对产品抗衰、美白和祛斑的效果影响较大;对比例2相比于实施例2而言,不添加肌肽、二裂酵母发酵产物溶胞物和1-甲基乙内酰脲-2-酰亚胺,对产品保湿、修护、抗衰、美白和祛斑的效果影响较大。
稳定性测试
对实施例1-3与对比例1-2进行了产品的稳定性测试,将在46℃以及-10℃下进行三个月的稳定性观察以及常温下进行3年的稳定性观察。
表2实施例1-3和对比例1-2在45℃和-10℃的稳定性测试
表3实施例1-3和对比例1-2在常温下经过6个月-36个月的稳定性测试
从表2-3的数据可以看出,实施例1-3在46℃和-10℃条件下形状和外观都没有发生改变,而且在常温条件下经过36个月也能保持形状和外观不发生变化。证明了本发明制备的美白膏霜的稳定性良好。
上述实施方式仅为本发明的优选实施方式,不能以此来限定本发明保护的范围,本领域的技术人员在本发明的基础上所做的任何非实质性的变化及替换均属于本发明所要求保护的范围。
Claims (10)
1.一种美白膏霜,其特征在于,由A相、B相、C相、D相和E相制成;
A相包括:多元醇3-10份、透明质酸钠0.01-0.5份、增稠剂0.1-0.5份、烟酰胺0.5-5份、尿囊素0.1-0.5份、EDTA二钠0.01-0.2份、对羟基苯乙酮0.1-0.5份和纯化水若干份;B相包括:乳化剂1-5份、氢化聚异丁烯2-5份、辛酸葵酸甘油三酯3-8份、牛油果树果脂1-3份、蜂蜡0.5-3份、生育酚乙酸酯0.1-1份、甲氧基肉桂酸乙基己酯0.5-3份、丁羟甲苯0.01-0.1份、鲸蜡硬脂醇0.5-3份;C相包括:增稠稳定剂0.2-1份;D相包括:柠檬酸0.1-1份、肌肽0.1-2份、凝血酸0.5-5份、二裂酵母发酵产物溶胞物0.1-5份、1-甲基乙内酰脲-2-酰亚胺0.1-3份、抗氧化剂0.01-0.2份、防腐剂0.6-1.5份和香精0.01-0.2份。
2.如权利要求1所述的美白膏霜,其特征在于,所述多元醇包括甘油、丁二醇、丙二醇中的一种或几种。
3.如权利要求1所述的美白膏霜,其特征在于,所述增稠剂包括卡波姆、丙烯酸(酯)类/C10-30烷醇丙烯酸酯交联聚合物和丙烯酸羟乙酯/丙烯酰二甲基牛磺酸钠共聚物中的一种或几种。
4.如权利要求1所述的美白膏霜,其特征在于,所述乳化剂包括主乳化剂和助乳化剂,主乳化剂和助乳化剂的重量比为1-3:1;其中,主化剂为C14-22醇和C12-20烷基葡糖苷的混合物;助乳化剂为甘油硬脂酸酯和PEG-100硬脂酸酯的混合物。
5.如权利要求4所述的美白膏霜,其特征在于,所述C14-22醇和C12-20烷基葡糖苷的重量比为1:1;甘油硬脂酸酯和PEG-100硬脂酸酯的重量比为1:1。
6.如权利要求1所述的美白膏霜,其特征在于,所述增稠稳定剂为重量比为4-7:2-4:1的丙烯酸钠/丙烯酰二甲基牛磺酸钠共聚物、异十六烷和聚山梨醇酯-80的混合物。
7.如权利要求1所述的美白膏霜,其特征在于,所述抗氧化剂为亚硫酸钠或焦亚硫酸钠。
8.如权利要求1所述的美白膏霜,其特征在于,所述防腐剂为重量比1:7-10:1的辛酰羟肟酸、1,3-丙二醇和甘油辛酸酯的混合物。
9.如权利要求1-8任一所述的美白膏霜的制备方法,其特征在于,包括以下步骤:
1)将A相中的对羟基苯乙酮加入多元醇中,加热到80-85℃中搅拌溶解;
2)将A相中的增稠剂和部分纯化水加入到水锅中,搅拌至增稠剂完全溶解,再加入烟酰胺、尿囊素、EDTA二钠和透明质酸钠,加热到80-85℃,搅拌溶解后加入步骤1)所得的溶液,继续搅拌保温,得到水相A;
3)将B相包括的全部原料加入到油锅中,加热搅拌,得到油相B;
4)将水相A加入乳化锅中,均质后,再加入油相B,均质,然后搅拌保温;
5)将步骤4)所得溶液降温至70℃,加入C相中的增稠稳定剂,均质,搅拌保温;
6)将A相剩余部分的纯化水加热到80-85℃,冷却到室温备用;
7)将D相中的柠檬酸加入到部分步骤6)所得的溶液中,充分溶解备用;
8)将D相中的肌肽加入到剩余的步骤6)所得的溶液中,充分溶解备用;
9)将步骤5)所得溶液冷却降温至40℃,加入步骤7)、步骤8)所得溶液和D相剩余的全部原料,搅拌溶解,冷却后即得美白膏霜。
10.如权利要求9所述的美白膏霜的制备方法,其特征在于,步骤9)中,冷却到35℃,取样检验,待检验合格后,进行灌装。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911283243.XA CN110897995A (zh) | 2019-12-13 | 2019-12-13 | 一种美白膏霜及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911283243.XA CN110897995A (zh) | 2019-12-13 | 2019-12-13 | 一种美白膏霜及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110897995A true CN110897995A (zh) | 2020-03-24 |
Family
ID=69825403
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911283243.XA Pending CN110897995A (zh) | 2019-12-13 | 2019-12-13 | 一种美白膏霜及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110897995A (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111671685A (zh) * | 2020-06-15 | 2020-09-18 | 广州市科昂贸易有限公司 | 一种美白祛斑组合物与美白祛斑霜及其制备方法 |
CN111939092A (zh) * | 2020-08-11 | 2020-11-17 | 广州市珍榜日用化工有限公司 | 一种用于初老型皮肤的修复沁肤乳及其制备方法与应用 |
CN112220717A (zh) * | 2020-10-16 | 2021-01-15 | 清远市华宝生物科技有限公司 | 一种美白防敏抗皱霜及其制备方法 |
CN112933011A (zh) * | 2021-03-04 | 2021-06-11 | 肌源匙(广东)皮肤管理科技有限公司 | 一种美白组合物及其制备工艺与应用 |
CN112933010A (zh) * | 2021-02-21 | 2021-06-11 | 广东贝诗特生物科技有限公司 | 一种美白修复霜及其制备方法 |
CN113230182A (zh) * | 2021-05-06 | 2021-08-10 | 广州市涵美化妆品有限公司 | 一种紧致修护面霜及其制备方法 |
CN115487122A (zh) * | 2021-11-09 | 2022-12-20 | 上海漫虹生物科技有限公司 | 一种天麻亮肤抗衰霜及其制备方法 |
CN115737477A (zh) * | 2023-01-06 | 2023-03-07 | 广州美尔生物科技有限公司 | 一种美白组合物、美白防腐组合物及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106333869A (zh) * | 2016-11-02 | 2017-01-18 | 广州美尔生物科技有限公司 | 一种具有美白祛斑作用的护肤品及其制备方法 |
CN109620763A (zh) * | 2019-01-18 | 2019-04-16 | 广州灵润生物科技有限公司 | 一种酵母多肽心机霜 |
CN110025528A (zh) * | 2019-04-24 | 2019-07-19 | 北京明弘科贸有限责任公司 | 一种不含去离子水的抗氧化美白精华液及其制备方法 |
CN110339137A (zh) * | 2019-08-29 | 2019-10-18 | 广州重生化妆品实业有限公司 | 一种酵母养颜精华素的配方及其制备方法 |
-
2019
- 2019-12-13 CN CN201911283243.XA patent/CN110897995A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106333869A (zh) * | 2016-11-02 | 2017-01-18 | 广州美尔生物科技有限公司 | 一种具有美白祛斑作用的护肤品及其制备方法 |
CN109620763A (zh) * | 2019-01-18 | 2019-04-16 | 广州灵润生物科技有限公司 | 一种酵母多肽心机霜 |
CN110025528A (zh) * | 2019-04-24 | 2019-07-19 | 北京明弘科贸有限责任公司 | 一种不含去离子水的抗氧化美白精华液及其制备方法 |
CN110339137A (zh) * | 2019-08-29 | 2019-10-18 | 广州重生化妆品实业有限公司 | 一种酵母养颜精华素的配方及其制备方法 |
Non-Patent Citations (1)
Title |
---|
深圳市琉璃光生物科技有限公司: "DANDIA臻美亮肤瓷肌珍奢霜,备案编号:粤G妆网备字2019191703", 《国产非特殊用途化妆品备案服务平台》 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111671685A (zh) * | 2020-06-15 | 2020-09-18 | 广州市科昂贸易有限公司 | 一种美白祛斑组合物与美白祛斑霜及其制备方法 |
CN111939092A (zh) * | 2020-08-11 | 2020-11-17 | 广州市珍榜日用化工有限公司 | 一种用于初老型皮肤的修复沁肤乳及其制备方法与应用 |
CN112220717A (zh) * | 2020-10-16 | 2021-01-15 | 清远市华宝生物科技有限公司 | 一种美白防敏抗皱霜及其制备方法 |
CN112933010A (zh) * | 2021-02-21 | 2021-06-11 | 广东贝诗特生物科技有限公司 | 一种美白修复霜及其制备方法 |
CN112933011A (zh) * | 2021-03-04 | 2021-06-11 | 肌源匙(广东)皮肤管理科技有限公司 | 一种美白组合物及其制备工艺与应用 |
CN112933011B (zh) * | 2021-03-04 | 2021-12-28 | 肌源匙(广东)皮肤管理科技有限公司 | 一种美白组合物及其制备工艺与应用 |
CN113230182A (zh) * | 2021-05-06 | 2021-08-10 | 广州市涵美化妆品有限公司 | 一种紧致修护面霜及其制备方法 |
CN113230182B (zh) * | 2021-05-06 | 2022-07-19 | 广州市涵美化妆品有限公司 | 一种紧致修护面霜及其制备方法 |
CN115487122A (zh) * | 2021-11-09 | 2022-12-20 | 上海漫虹生物科技有限公司 | 一种天麻亮肤抗衰霜及其制备方法 |
CN115737477A (zh) * | 2023-01-06 | 2023-03-07 | 广州美尔生物科技有限公司 | 一种美白组合物、美白防腐组合物及其应用 |
CN115737477B (zh) * | 2023-01-06 | 2023-04-07 | 广州美尔生物科技有限公司 | 一种美白组合物、美白防腐组合物及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110897995A (zh) | 一种美白膏霜及其制备方法 | |
CN108524377A (zh) | 一种美白组合物及其面霜 | |
US20080305057A1 (en) | New and improved skin treatment systems | |
CN110638707A (zh) | 一种眼部护理霜及其制备方法 | |
CN104434707A (zh) | 美白祛斑精华 | |
CN110664644B (zh) | 一种含叶酸的护肤组合物、精华及其制备方法 | |
CN112120986A (zh) | 一种眼部修护组合物及含有该组合物的眼霜 | |
CN112569133A (zh) | 紧致抗皱精华霜及其制备方法 | |
CN110721120A (zh) | 一种多功能护肤膏及其制备方法 | |
CN112641670A (zh) | 保湿精华乳及其制备方法 | |
CN110693778A (zh) | 一种面霜及其生产工艺 | |
CN108771643B (zh) | 盈润修护精华 | |
CN112120949B (zh) | 一种水光保湿精华液及其制备方法 | |
CN112773761B (zh) | 一种化妆品组合物、精华液及其制备方法 | |
CN111773174B (zh) | 修护霜及其制备方法 | |
CN112353705B (zh) | 化妆品组合物及其制备方法和具有祛皱、延缓衰老功效的化妆品 | |
KR20140089266A (ko) | 피부미용 효능을 가지는 영양크림 조성물 | |
CN112754963A (zh) | 紧致抗皱护肤品的使用方法 | |
CN111991251A (zh) | 一种补水棒及其制备方法 | |
CN116889528A (zh) | 一种水光面膜及其制备方法 | |
CN111973501A (zh) | 一种神经酰胺赋活乳及其制备方法 | |
CN114632028B (zh) | 一种提拉紧致面霜及其制备方法 | |
CN114159333B (zh) | 一种肌底液及其制备方法 | |
CN114288201B (zh) | 一种祛眼袋、淡化黑眼圈的组合物及其制备方法和应用 | |
CN115089537A (zh) | 一种深度修护精华液及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200324 |